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Introduction
Intense immunosuppression followed by autologous hemat-
opoietic stem cell transplantation (aHSCT) is a potential 
treatment for patients suffering from aggressive multiple 
sclerosis (MS).1 aHSCT is able to induce a long-lasting 
remission of inflammatory disease activity, which can per-
sist years beyond complete immune reconstitution. The 
rationale for aHSCT in MS is based on the concept that lym-
pho-/myeloablative conditioning eliminates pathogenic 
autoreactive immune cells and facilitates the regeneration of 
a new and tolerant immune system from CD34+ hematopoi-
etic progenitor cells (HPC). In fact, thorough analysis of the 
T cell repertoire in the regenerating immune system after 
aHSCT in MS supports that a new and antigen-naïve T cell 
repertoire develops from the HPC compartment via thymic 
regeneration.2 To date, it remains unresolved whether auto-
immunity in MS is merely a consequence of loss of periph-
eral immune tolerance or whether it results from immune 
dysregulation, which is already predetermined in HPC. To 
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Abstract
Autologous hematopoietic stem cell transplantation (aHSCT) has been used as a therapeutic approach in multiple sclero-
sis (MS). However, it is still unclear if the immune system that emerges from autologous CD34+ hematopoietic progeni-
tor cells (HPC) of MS patients is pre-conditioned to re-develop the proinflammatory phenotype. The objective of this 
article is to compare the whole genome gene and microRNA expression signature in CD34+ HPC of MS patients and 
healthy donors (HD). CD34+ HPC were isolated from peripheral blood of eight MS patients and five HD and analyzed 
by whole genome gene expression and microRNA expression microarray. Among the differentially expressed genes 
(DEGs) only TNNT1 reached statistical significance (logFC=3.1, p<0.01). The microRNA expression was not significantly 
different between MS patients and HD. We did not find significant alterations of gene expression or microRNA profiles 
in CD34+ HPCs of MS patients. Our results support the use of aHSCT for treatment of MS.
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approach this key point we compared the global gene- and 
miRNA expression profiles of CD34+ and CD34- cells col-
lected from MS patients and healthy donors (HD).
Patients and methods
Patients and controls
MS patients (n=8) with relapsing–remitting (RRMS) or 
secondary-progressive (SPMS) disease (mean disease 
duration 10 years, range 6–16 years) were treated with 
aHSCT at the University of Hamburg, Germany (four 
female SPMS) and the Haematology Unit, Careggi Hospital 
of Florence, Italy (two male RRMS and two female SPMS). 
All patients had previously received immunomodulatory 
and/or immunosuppressive therapy. Control HPC samples 
were obtained from five age-matched HD (three female). 
All patients provided written informed consent and all 
study protocols were in accordance with the Declaration of 
Helsinki and approved by Institutional Review Boards at 
each centre.
Mobilization and collection of CD34+ cells
Before collecting HPC from peripheral blood by leukocyta-
pheresis, the Hamburg MS cohort and the five HD were 
mobilized with subcutaneous injection of granulocyte col-
ony-stimulating factor (G-CSF) analogue (2x5µg/kg/day) 
for 5–8 days. The Florence cohort was mobilized with 
intravenous cyclophosphamide (Cy, 4g/m2) and G-CSF 
(5µg/kg/day) until cell harvest by leukocytapheresis. Cell 
collections were frozen in liquid nitrogen according to 
standard procedures.3,4 All samples were thawed and pro-
cessed at one centre by a standardized protocol and CD34+ 
HPC purified by magnetic bead separation using the 
autoMACS system (Miltenyi). The control samples 
consisted of the remaining CD34- negative cell fraction 
after magnetic bead separation, i.e. a population of periph-
eral blood mononuclear cells. Purity and viability of CD34+ 
cells were analyzed by FACS and revealed a mean of 84.8% 
(range 73.5 – 89.7%) viable CD34+ cells. There was no 
difference in the purity or viability of cells between MS 
patients and HD (see supplemental methods).
Microarray analysis
Whole genome gene expression was analyzed with the 
Human 4x44K Design Array (Agilent-Technologies). 
Differentially expressed genes (DEGs) of interest were 
confirmed by quantitative rtPCR. miRNA profiling was 
performed with the Human miRNA Array V2.0 (Agilent-
Technologies). The microarray data were generated con-
forming to the MIAME guidelines and are deposited in the 
Gene Expression Omnibus database (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE27694).
Statistics and bioinformatics
Standard microarray analysis methods were used for pro-
cessing intensity data and normalization (see supplemental 
methods).5 Individual genes were considered differentially 
expressed above a fold-change of 1.7 (logFC>0.7). P-values 
were corrected for multiple testing.6 miRNA data were ana-
lyzed in an analogous way.
Results
Gene expression analysis
Principal component analysis (PCA) confirmed separation 
between CD34+ and CD34- samples and showed a clear clus-
tering of CD34+ cells according to the mobilization regimen 
Figure 1. Principal component analysis (PCA) of CD34 positive cells and CD34 negative cells according to mobilization regimen. 
PCA of CD34 negative and CD34 positive cells from G-CSF treated (light grey) and G-CSF/Cy treated (dark grey) MS patients 
(circle) and G-CSF treated healthy donors (rhombus) shows a clear separation of samples according to the mobilization regimen.
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(Cy/G-CSF versus G-CSF; Figure 1). Accordingly, we found 
2801 DEGs in CD34+ (adj.p-value≤0.05) and 9440 DEGs in 
CD34- (adj p-value≤0.05) cells comparing MS patients mobi-
lized with G-CSF only or Cy/G-CSF, respectively.
Comparing DEGs in CD34+ HPC of MS patients and 
HD, both mobilized with G-CSF only, we found 297 DEGs 
(logFC>0.7), but the TNNT1 gene was the only DEG with 
statistical significance after Benjamini-Hochberg correc-
tion (logFC=3.1, adj.p<0.01; Table 1).
Comparing CD34- cells between MS and HD we found 
167 DEGs (logFC>0.7), however none reached statistical 
significance.
miRNA expression analysis
miRNA expression was analyzed in samples obtained from 
MS patients mobilized with G-CSF only and HD mobilized 
with G-CSF only. None of the miRNA showed statistically 
significant differential expression levels comparing MS 
patients and HD mobilized with G-CSF only.
Discussion
The immunologic rationale for aHSCT as treatment for 
autoimmune diseases like MS is being discussed intensively 
Table 1. Ten most up- and down-regulated genes in CD34+ HPCs comparing MS patients and healthy donors.
Gene symbol Description logFC p-value1 Function
Upregulated
TNNT1 Troponin T type 1 (skeletal, slow) 3.197 0.00000012 Subunit of troponin, striated muscle con-
traction
FOXE1 Forkhead box E1 (thyroid tran-
scription factor 2)
2.269 0.02534 Thyroid transcription factor
HLA-DQB1 Major histocompatibility complex 
class II. DQ beta
1.922 0.00560 HLA class II beta chain, expressed in antigen 
presenting cells
SOX17 SRY (sex determining region Y)-
box 17
1.869 0.03167 Transcription factor, determination of the 
cell fate
GPR141 G protein-coupled receptor 141 1.780 0.11199 Rhodopsin family of G protein-coupled 
receptors
NEUROG1 Neurogenin 1 1.771 0.05177 Promotes neurogenesis, inhibits astrocyte 
differentiation
LOC647121 Embigin homolog (mouse) pseu-
dogene
1.696 0.02507 Not known
TNXB Tenascin XB 1.587 0.06001 Extracellular matrix glycoprotein, anti-
adhesive effect
DKFZP434I0714 Hypothetical protein DKFZ-
P434I0714
1.574 0.04861 Not known
ZSCAN10 Zinc finger and SCAN domain 
containing 10
1.568 0.07729 Transcription factor, metal ion binding
Downregulated
DDX3Y DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3
–2.454 0.14760 Putative RNA helicases
PRSS21 Protease.serine. 21 (testisin) –2.209 0.00003 Cell-surface anchored serine protease
CTSG Cathepsin G –1.983 0.04575 Member of the peptidase S1 protein family, 
neutrophil granulocytes
MPO Myeloperoxidase –1.909 0.00095 Neutrophil azurophilic granules, microbi-
cidal activity
FAM78A Family with sequence similarity 
78.member A
–1.844 0.06178 Not known
EIF1AY Eukaryotic translation initiation 
factor 1A
–1.695 0.09977 Eukaryotic translation initiation factor
JARID1D Jumonji. AT rich interactive  
domain 1D
–1.692 0.06539 Protein containing zinc finger domains
CYorf15A Chromosome Y open reading 
frame 15A
–1.580 0.09665 Not known
ELA2 Elastase 2.neutrophil –1.516 0.00429 Serine protease, neutrophil granulocytes
DNTT Deoxynucleotidyltransferase.
terminal
–1.428 0.00428 Template-independent DNA polymerase
HPCs: hematopoietic progenitor cells; logFC: log fold change; 1: p-value (not adjusted); 2: only gene which maintained statistical significance after cor-
rection (Benjamini-Hochberg). 
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among basic and clinical immunologists in recent years.2,7,8 
A key issue has been the question whether replacement of 
the autoreactive immune system by autologous HPC is able 
to stop the autoimmune process for long or forever, or alter-
natively whether the autoaggressive immunity will rebound 
after hematologic reconstitution. If the latter occurred it 
would indicate that the autoimmune process is pre-pro-
grammed in HPCs of genetically predisposed individuals 
rather than evolving at the stage of mature T cells and in the 
peripheral immune system. In this study we approached 
this question by comparing the gene expression profile of 
CD34+ HPCs collected from MS patients before autolo-
gous transplantation with CD34+ HPCs or from HDs. To 
the best of our knowledge, this is the first study to analyze 
the gene expression profile of CD34+ HPC in an autoim-
mune disease.
The results of this study support the view that HPC of 
MS patients are not pre-conditioned towards autoim-
munity. We did not find significant alteration in the gene 
expression profile of CD34+ HPC in MS. Only one DEG 
(TNNT1) maintained statistical significance after correc-
tion for multiple comparisons (Table 1). TNNT1 encodes 
a subunit of troponins involved in contraction of slow 
skeletal muscle. Of note, the TNNT1 gene is expressed 
on chromosome 19q13, which carries predisposing loci 
for several autoimmune diseases, but with conflicting 
results in MS.9–11 A recent genome-wide association 
study did not find SNPs (single nucleotide polymor-
phism) associated with MS in the TNNT1 gene.12
Comparison of miRNA expression profiles of CD34+ 
HPC between MS and HD did not reveal statistically sig-
nificant differences, thereby corroborating our DEG results 
lacking substantial alterations in CD34+ cells in MS. There 
were no statistically significant DEGs in CD34- cells com-
paring MS and HD. The interpretation of our results must 
consider that the mobilization regimen with G-CSF pro-
vides a strong stimulus to the peripheral immune compart-
ments and the stem cell niche and might thereby overshadow 
more subtle differences in the gene expression pattern of 
CD34- and CD34+ cells. Currently, experts recommend 
that the mobilization regimen for HSCT in MS should 
include G-CSF and cyclophosphamide, which precludes 
any comparison with HD. Since the mobilization regimen 
clearly influenced gene expression and HD are always 
mobilized by G-CSF only, our patient cohort provided a 
unique opportunity to directly compare the gene and 
miRNA expression profile of highly purified CD34+ cells 
from MS patients with HD. Consistent with our results, it 
has been shown that both the gene and miRNA expression 
differ depending on the stem-cell source and the mobiliza-
tion regimen used.13–15 Studies analyzing gene and miRNA 
expression in hematopoiesis or hematological malignancies 
mainly used HPC obtained by bone marrow aspiration or 
from in-vitro cultured cells, precluding a direct comparison 
with our results. A caveat in the interpretation of our study 
is the small number of samples, which leaves the possibility 
of a false negative result.
In summary, we did not find significant alterations of 
gene expression or miRNA profiles in CD34+ HPCs of MS 
patients. Thus, we provide evidence that the immune devia-
tion seen in the peripheral immune system in MS patients is 
probably not at the CD34+ precursor cell stage. One must 
consider that the immune changes seen in MS may repre-
sent a secondary response to a primary CNS pathology. 
Nevertheless, we feel that the lack of significant alterations 
of gene expression or miRNA profiles in CD34+ HPCs of 
MS patients supports the use of autologous HPC for HSCT 
in MS.
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